Details of the Drug Reposition

General Information of This Drug (ID: DM047HI)

Drug Name
Vamorolone   DM047HI
Synonyms
vamorolone; 13209-41-1; UNII-8XP29XMB43; VBP-15; 8XP29XMB43; CHEMBL2348780; 17,21-Dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione; A-Methyl-9,11-dehydro Prednisolone; (8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one; Vamorolone [USAN]; VBP-15 free alcohol; VBP 15; EINECS 236-177-8; AC1MHYKY; Vamorolone (USAN/INN); SCHEMBL143459; GTPL9247; A)-17,21-dihydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione; ZINC33650317
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Duchenne muscular dystrophy DISRQ3NV 8C70.1 Approved [1]
------------------------------------------------------------------------------------
3 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Multiple sclerosis DISB2WZI 8A40 Phase 1 [2]
Inflammatory bowel disease DISGN23E DD72 Phase 1 [2]
Rheumatoid arthritis DISTSB4J FA20 Phase 1 [2]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 215239
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)